Brokerages Set ADMA Biologics Inc (NASDAQ:ADMA) Target Price at $19.67

ADMA Biologics Inc (NASDAQ:ADMA) has received a consensus rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $19.6667.

A number of equities research analysts have issued reports on ADMA shares. Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Raymond James Financial assumed coverage on ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective on the stock. Mizuho reduced their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th.

Insiders Place Their Bets

In related news, Director Jerrold B. Grossman purchased 12,500 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the acquisition, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently made changes to their positions in ADMA. Royal Bank of Canada increased its stake in shares of ADMA Biologics by 112.7% during the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock worth $1,903,000 after buying an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC purchased a new position in ADMA Biologics in the first quarter worth approximately $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in ADMA Biologics by 59.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after acquiring an additional 305,064 shares in the last quarter. Norges Bank acquired a new position in ADMA Biologics during the 2nd quarter worth approximately $549,000. Finally, EverSource Wealth Advisors LLC increased its position in shares of ADMA Biologics by 385.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,180 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $8.95 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The firm has a market capitalization of $2.07 billion, a PE ratio of 13.16 and a beta of 0.73. The firm’s 50-day moving average is $8.70 and its two-hundred day moving average is $13.01. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. The business had revenue of $114.49 million during the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.11 earnings per share. Analysts predict that ADMA Biologics will post 0.82 EPS for the current year.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Bronstein, Schall, Glancy Prongay, Berger Montague, KSF, Faruqi & Faruqi, and Kirby McInerney, issued reminders about the ongoing ADMA Biologics securities class action and the approaching August 10 lead plaintiff deadline. Article: Rosen, National Investor Counsel, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ADMA
• Neutral Sentiment: The complaints allege violations of federal securities laws and claim investors who bought ADMA shares during the class period may have suffered losses, which keeps legal risk in focus. Article: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Neutral Sentiment: One filing specifically alleges ADMA made misrepresentations about its revenue sources, adding to concerns about the company’s prior disclosures. Article: ADMA Shareholder News: ADMA Biologics Accused of Making Misrepresentations about its Revenue Sources in Securities Fraud Class Action

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.